VIENNA, Austria and KING OF PRUSSIA, Pa., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, provided a development update and reported today its financial results for the nine months ended September 30, 2015.
“We have been successfully executing on our lefamulin development program,” said Dr. Colin Broom, Chief Executive Officer of Nabriva, “and I am delighted to add that we have initiated the first of our two pivotal, Phase 3 clinical trials of lefamulin for the treatment of patients with moderate to severe Community Acquired Bacterial Pneumonia (CABP). This should allow us to take advantage of the winter season in the northern hemisphere, and we plan to add additional sites, including southern hemisphere sites, over the next few months. We expect that the net proceeds from our recently completed initial public offering (IPO), together with our other cash resources, will be sufficient to enable us to fund our operations at least through the receipt of top-line clinical data from these Phase 3 CABP trials, which we anticipate in late 2017.”
Help employers find you! Check out all the jobs and post your resume.
